News Releases | Lexicon Pharmaceuticals, Inc.

Press Releases

Title	Published Date
Zynquista™ Now Approved in the European Union for Treatment of Adults with Type 1 Diabetes	Apr 26, 2019
Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019	Apr 25, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Apr 02, 2019
Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes	Mar 22, 2019
FDA Issues Complete Response Letter for Zynquista™ (Sotagliflozin)	Mar 22, 2019
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer	Mar 15, 2019
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update	Mar 13, 2019
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019	Mar 11, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Mar 11, 2019
CHMP Recommends Zynquista™ (Sotagliflozin) for the Treatment of Adults with Type 1 Diabetes	Mar 01, 2019